HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Halozyme Therapeutics Inc (HALO) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, declining financial performance, and significant insider and hedge fund selling activity. While analysts have raised price targets recently, the lack of positive short-term catalysts and mixed sentiment make it prudent to hold off on buying for now.
The MACD is negatively expanding (-1.228), RSI is at 22.041 (neutral zone), and moving averages are converging, indicating no clear bullish momentum. The stock is trading near its key support level (S1: 69.403), and the price trend is weak with a -1.61% regular market change and a -0.32% post-market change.
Analysts have recently raised price targets, with a consensus view of strong 2026 performance driven by royalty revenues and partnerships. The company's ENHANZE technology and acquisitions (Hypercon and Surf Bio) are seen as potential growth drivers.
Insiders and hedge funds are selling aggressively, with insider selling increasing by 2642.71% and hedge fund selling up by 4215.85%. Financial performance in Q4 2025 showed a significant decline in net income (-203.34% YoY) and EPS (-213.21% YoY), raising concerns about profitability. Additionally, Goldman Sachs downgraded the stock to 'Sell,' citing long-term risks to the royalty model post-2030.
In Q4 2025, revenue increased by 51.60% YoY to $451.77M, but net income dropped to -$141.59M (-203.34% YoY), and EPS fell to -1.2 (-213.21% YoY). Gross margin also declined slightly to 77.39% (-3.18% YoY), reflecting worsening profitability despite revenue growth.
Recent analyst ratings are generally positive, with price targets raised by Benchmark ($90), Morgan Stanley ($94), and TD Cowen ($90). However, Wells Fargo maintains an Equal Weight rating, and Goldman Sachs downgraded the stock to 'Sell' with a $56 target, citing long-term risks to the royalty model.
